TNF Pharmaceuticals Inc (TNFA) News

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

Series of studies to observe signals of inflammation and TNF-alpha levels in patients taking GLP-1s including Wegovy® or Ozempic® Lean body mass...

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty Transformative potential for novel...

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

Fully funded study to evaluate Wegovy and Ozempic patients at risk for increased inflammation associated with sarcopenic muscle deterioration...

Premarket Action Is Heating Up For This Biotech

A Maryland-based biotech company found very early success during Tuesday’s premarket hours a day after the company reported statistically...

TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

Based on successful Phase 2a data, Company set to initiate Phase 2b sarcopenia study in early 2025; currently securing centers of excellence to...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market

Prevail Partners, LLC investment priced at more than a 40% premium to market Prevail InfoWorks, Inc. to act as Clinical Research Organization...

Form 8-K - Current report

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

MYMD-1® development to continue through fully funded mid-stage clinical trials Clinical study of MYMD-1 in sarcopenia/frailty met primary...